EC序贯T方案用于乳腺癌根治术后患者化疗的效果及安全性

目的探讨EC序贯T方案(表柔比星+环磷酰胺,序贯多西他赛)对乳腺癌根治术后患者的疗效及安全性。方法选取2015年1月-2018年1月在辽宁省某医院行乳腺癌根治术后接受化疗的88例患者为研究对象,根据术后化疗方案分为研究组(n=46)和对照组(n=42)。对照组患者术后接受TEC方案(多西他赛+表柔比星+环磷酰胺)化疗,研究组患者术后接受EC序贯T方案化疗,比较2组患者近期临床疗效、化疗期间毒副反应发生情况及化疗结束1个月时的生存质量。结果研究组患者临床总有效率(RR)为73.91%(34/46),肿瘤控制率(DSR)为91.30%(42/46),高于对照组患者的52.38%(22/42)及73.81%(31/42),差异均有统计学意义(P<0.05)。研究组患者在化疗过程中的白细胞减少发生率为50.00%(23/46),血小板减少发生率为45.65%(21/46),低于对照组的66.67%(28/42)及69.05%(29/42),差异均有统计学意义(P<0.05)。化疗结束1个月时,研究组患者癌症治疗功能评价量表(FACT-G)量表中生理状况、社会/家庭状况、情感状况及功能状况维度评分及总分均高于对照组,差异均有统计学意义(P<0.05)。结论乳腺癌根治术后患者接受EC序贯T方案化疗的近期疗效较TEC方案更优,且可降低白细胞减少与血小板减少等毒副反应发生率,有利于提高患者生存质量。

Efficacy and safety of EC sequential T regimen in patients after radical mastectomy

Objective To explore the efficacy and safety of EC sequential T regimen(epirubicin+cyclophosphamide,sequential taxotere)in patients with radical mastectomy.Methods Eighty-eight patients who underwent chemotherapy after radical mastectomy in a hospital in Liaoning Province were selected for the study.The patients were divided into study group(n=46)and control group(n=42)according to the postoperative chemotherapy regimens.Patients in control group received TEC regimen(taxotere+epirubicin+cyclophosphamide)after surgery,and patients in study group received EC sequential T regimen chemotherapy after surgery.The short-term clinical efficacy,occurrence of toxic and side effects during chemotherapy and quality of life after 1 month at the end of chemotherapy were compared between the two groups.Results The RR and DSR were 73.91%(34/46)and 91.30%(42/46)in study group,which were higher than those in control group with 52.38%(22/42)and 73.81%(31/42)(P<0.05).During chemotherapy,the incidence rates of leukopenia and thrombocytopenia were 50.00%(23/46)and 45.65%(21/46)in study group,which were lower than those in control group with 66.67%(28/42)and 66.67%(28/42)(P<0.05).After 1 month at the end of chemotherapy,the scores of survival status,social/family status,emotional status and functional status and total score of Functional Assessment of Cancer Therapy-General(FACT-G)in study group were higher than those in control group(P<0.05).Conclusion EC sequential T regimen chemotherapy has better short-term efficacy of patients after radical mastectomy than TEC regimen,and it can reduce the incidence rates of toxic and side effects of leukopenia and thrombocytopenia,and can help improve the quality of life of patients.